Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients: data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium : Real-World-Daten aus dem PRAEGNANT-Register
Background: Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone receptor-positive (HER2− HR+) breast cancer patients in...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2022-07-12
|
| In: |
Geburtshilfe und Frauenheilkunde
Year: 2022, Volume: 82, Issue: 10, Pages: 1055-1067 |
| ISSN: | 1438-8804 |
| DOI: | 10.1055/a-1880-0087 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1880-0087 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1880-0087 
|
| Author Notes: | authors: Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss |
| Summary: | Background: Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone receptor-positive (HER2− HR+) breast cancer patients in the first-line advanced therapy setting. Data on patient populations that have been treated in the real-world setting may provide an insight into changes of patient characteristics and prognosis over time. Methods: The data were extracted from the prospective real-world registry PRAEGNANT (NCT02338167). Patients had to have HER2− HR+ advanced breast cancer in the first-line metastatic setting. The chosen therapies were described as well as progression-free survival (PFS) and overall survival (OS) in relation to the given therapies and time periods during which they were indicated.</p> <p> <b>Results</b> CDK4/6 inhibitors have been rapidly implemented since their introduction in November 2016. In recent years (2018 - 2022), about 70 - 80% of the patient population have been treated with CDK4/6 inhibitors, while endocrine monotherapy was given to about 10% and chemotherapy to about 15% of all patients. The prognosis was worst in patients treated with chemotherapy. Recently, mainly patients with a good prognosis are being treated with endocrine monotherapy, and patients who are treated with chemotherapy have an unfavorable prognosis. The PFS and OS of patients treated with CDK4/6i + ET have remained similar over time despite changes in patient characteristics. Conclusion: A treatment with CDK4/6i + ET has rapidly become the therapy standard for patients in the first-line advanced breast cancer setting. After the implementation of CDK4/6i + ET, endocrine monotherapy is only given to patients with a very favorable prognosis, while chemotherapy is provided to patients with a rather unfavorable prognosis. These changes in patient characteristics did not seem to influence the prognosis of patients treated with CDK4/6i + ET. |
|---|---|
| Item Description: | Gesehen am 09.02.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1438-8804 |
| DOI: | 10.1055/a-1880-0087 |